Sun Pharmaceuticals Industries Limited
2008-09 vs 2009-10
Comparison
The financial results of Sun Pharma –both consolidated and consolidated are below :
Consolidated net sales has come down by 3.97 percent. But, total expenditure has increased by 14.28 percent. Consequently consolidated net profit has come down by 25.74 percent.
Consolidated EPS has come down to 65.2 from 87.8, a fall of 25.74 percent YOY.
FY10( lakhs) | %age | |||||
Net Sales | 410277 | 427230 | -3.97 | |||
Raw Materials | 99323 | 89368 | 11.14 | |||
Traded goods | 13704 | 5693 | 140.72 | |||
Employees Cost | 48221 | 43986 | 9.63 | |||
Depreciation | 15331 | 12329 | 24.35 | |||
Other Expenditure | 115992 | 111168 | 4.34 | |||
Total Expenditure | 289327 | 253171 | 14.28 | |||
O P T | 120950 | 174059 | -30.51 | |||
Other Income | 9145 | 8684 | 5.31 | |||
Interest | -11389 | -12174 | -6.45 | |||
Net Profit | 134698 | 187801 | -28.28 | |||
Consolidated NPT | 135108 | 181773 | -25.67 | |||
Face Value (in Rs.) | 5 | 5 | 0 | |||
Paid-up Equity | 10356 | 10356 | 0 | |||
Reserves | 772535 | 694136 | 11.29 | |||
Basic EPS | 65.2 | 87.8 | -25.74 | |||
STAND ALONE RESULTS
The stand alone Net sales has come down more steeply by 33.35 percent. Total expenditure has also come down by 39.44 percent. Consequently, stand alone net profit is down by 28.98 percent. The stand alone Basic EPS is down by 28.97 percent to 43.4 in FY 10 from 61.1 in FY 09. The reason for this all-round downturn in performance in FY10 - specially in sales needs further analysis and clarification from Management.
Sun Pharma had earlier lost some patent cases in US courts and also its US subsidiary seems to have been asked to stop production by the US drug regulator last year for not sorting out irregularities in manufacturing units. The latest position on these cases is not clear. Whether these are responsible for the lower sales, and profits is to be clarified.
Sun Pharma is currently quoting at Rs.1540, at a PE ratio of 23.62 to its consolidated EPS and35.48 to its stand alone EPS.
FY10lakhs | %age | ||
Net Sales | 184613 | 276975 | -33.35 |
Other Oprtg Income | 67766 | 109180 | -37.93 |
Raw Materials | 70926 | 66425 | 6.78 |
Traded goods | 13704 | 127067 | -89.22 |
Other Expenditure | 56759 | 59926 | -5.28 |
Total Expenditure | 166460 | 274861 | -39.44 |
O P T | 85919 | 111294 | -22.8 |
Net Profit | 89865 | 126529 | -28.98 |
Dividend (%) | 275 | 275 | 0 |
Face Value (in Rs.) | 5 | 5 | 0 |
Paid-up Equity | 10356 | 10356 | 0 |
Reserves | 561442 | 504786 | 11.22 |
Basic EPS | 43.4 | 61.1 | -28.97 |
AVAILABLE
QUARTERLY RESULTS
COMPARISON
2009DEC | 2009SEP | 2009JUNE | 2008 DEC | 2008 SEP | |
Net Sales | 48964 | 47439 | 40588 | 63106 | 69753 |
Other Operating Income | 21280 | 18974 | 7087 | 23187 | 23184 |
Raw Materials | 14287 | 20957 | 15736 | 17349 | 16219 |
Traded Goods | 5254 | 1991 | 2408 | 28912 | 29423 |
Employees Cost | 5237 | 5301 | 5148 | 4662 | 4812 |
Depreciation | 1540 | 1662 | 1726 | 1440 | 1460 |
Other Expenditure | 12969 | 21087 | 13487 | 14679 | 15728 |
Total Expenditure | 38337 | 48760 | 39721 | 63773 | 67899 |
Net Profit | 31804 | 20306 | 12151 | 25668 | 30314 |
Dividend (%) | - | - | - | - | - |
Face Value (In Rs | 5 | 5 | 5 | 5 | 5 |
Paid Up Equity | 10356 | 10356 | 10356 | 10356 | 10356 |
Reserves | - | - | - | - | - |
Basic EPS | 15.4 | 9.8 | 5.9 | 12.4 | 14.6 |
ANNOUNCEMENTS TO THE EXCHANGE
24-05-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange regarding a press release dated May 24, 2010, titled "Sun Pharma reports 2009-10 financials, Net sales Rs.4103 crores, Net Profit Rs.1351 crores, R&D Spend Rs.247 crores".
24-05-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange that the Board of Directors at its Meeting held on May 24, 2010 have recommended payment of dividend of Rs. 13.75 per equity share of Rs. 5/- each of the Company for the year ended March 31, 2010 subject to the approval of the members at the ensuing Annual General Meeting of the Company. -
24-05-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 410277 lacs for year ending on 31-MAR-2010 against Rs. 427230 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 135108 lacs for the year ending on 31-MAR-2010 against Rs. 181773 lacs for the year ending on 31-MAR-2009. -
24-05-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 184613 lacs for year ending on 31-MAR-2010 against Rs. 276975 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 89865 lacs for the year ending on 31-MAR-2010 against Rs. 126529 lacs for the year ending on 31-MAR-2009. -
17-05-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange regarding a press release dated May 17, 2010, titled "Sun Pharma to announce Q4FY10 results on May 24, 2010".
06-05-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange regarding a press release dated May 06, 2010, titled " Sun Pharma announces USFDA approval for generic Namenda® tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
26-04-2010 Sun Pharmaceuticals Industries Limited has informed the Exchange regarding a press release dated April 24, 2010, titled " Sun Pharma : An update on generic Protonix(R) litigation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). -
12-04-2010 Sun Pharmaceuticals Industries Ltd has informed the Exchange regarding a press release dated April 10, 2010, titled " Sun Pharma announces USFDA tentative approval for generic Namenda(R) tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
08-04-2010 Sun Pharmaceuticals Industries Ltd has informed the Exchange regarding a press release dated April 08, 2010, titled " Sun Pharma announces USFDA approval for generic Wellbutrin SR(R) extended release tablets".
18-03-2010 Sun Pharmaceuticals Industries Ltd has informed the Exchange regarding a press release dated March 18, 2010, titled " Sun Pharma announces USFDA approval for generic Prometh Syrup ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
29-01-2010 Sun Pharmaceuticals Industries Ltd has informed the Exchange regarding a press release dated January 29, 2010, titled "Sun Pharma reports Q3 2009-10 financials; Q3: Net sales Rs.1021 crores, Net profit Rs.339 crores". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
No comments:
Post a Comment